MARKER THERAPEUTICS (MRKR)
(Delayed Data from NSDQ)
$2.93 USD
+0.16 (5.78%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $2.90 -0.03 (-1.02%) 6:04 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Income Statements
Fiscal Year end for MARKER THERAPEUTICS, INC falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 3 | 9 | 1 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 3 | 9 | 1 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 18 | 39 | 41 | 29 | 23 |
Income After Depreciation & Amortization | -15 | -30 | -39 | -29 | -23 |
Non-Operating Income | 1 | 0 | -2 | 0 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -14 | -30 | -42 | -29 | -21 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -14 | -30 | -42 | -29 | -21 |
Extras & Discontinued Operations | 6 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -8 | -30 | -42 | -29 | -21 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -15 | -26 | -36 | -28 | -22 |
Depreciation & Amortization (Cash Flow) | 0 | 4 | 3 | 1 | 0 |
Income After Depreciation & Amortization | -15 | -30 | -39 | -29 | -23 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 8.81 | 8.35 | 7.65 | 4.70 | 4.56 |
Diluted EPS Before Non-Recurring Items | -1.59 | -3.58 | -5.20 | -6.10 | -4.70 |
Diluted Net EPS (GAAP) | -0.94 | -3.58 | -5.50 | -6.10 | -4.70 |
Fiscal Year end for MARKER THERAPEUTICS, INC falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 1.17 | 1.24 | -2.44 | 0.26 | 0.76 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 1.17 | 1.24 | -2.44 | 0.26 | 0.76 |
SG&A, R&D, and Dept/Amort Expenses | 3.48 | 3.80 | -0.25 | 3.45 | 4.90 |
Income After SG&A, R&D, and Dept/Amort Expenses | -2.31 | -2.56 | -2.19 | -3.19 | -4.14 |
Non-Operating Income | 0.12 | 0.16 | 0.20 | 0.22 | 0.04 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -2.19 | -2.39 | -1.99 | -2.98 | -4.10 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -2.19 | -2.39 | -2.00 | -2.98 | -4.10 |
Extras & Discontinued Operations | 0.00 | 0.00 | -0.81 | 0.00 | 6.61 |
Net Income (GAAP) | -2.19 | -2.39 | -2.80 | -2.98 | 2.52 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 8.92 | 8.90 | NA | 8.83 | 8.80 |
Diluted EPS Before Non-Recurring Items | -0.25 | -0.27 | NA | -0.34 | -0.47 |
Diluted Net EPS (GAAP) | -0.25 | -0.27 | -0.32 | -0.34 | 0.29 |